Skip to main content
S&P 5007,656.98+0.86%DOW52,573.29+0.98%NASDAQ26,333.03+0.96%BTC$77,267.00+0.58%ETH$2,510.86+2.27%GOLD$4,390.00-0.39%OIL$99.99-2.43%
Smart Investors Daily
AO

NYSE · AORT

Artivion, Inc.

Healthcare · Medical - Devices

$25.08

Up+$0.43 (+1.74%)

Updated Sep 14, 2026, 2:40 AM

SID Score

3.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.84B
P/E ratio
187.45
Dividend yield
0.00%
52-week range
$19.16 – $39.66
Volume
547.89K
Avg. volume
384.16K

Price performance

AORT price history

1M range · 19 trading sessions · Daily adjusted prices

AORT closed at $25.08 after 19 trading sessions, down 11.44% for the selected period.

Last close
$25.08
Period change
-11.44%
Period low
$24.65
Period high
$28.90
Daily close
View OHLC price history
AORT OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 11, 2026$24.96$25.28$24.40$25.08547.89K
Sep 10, 2026$25.12$25.40$24.5038$24.65694.54K
Sep 9, 2026$25.15$25.72$24.72$25.22553.8K
Sep 8, 2026$25.42$25.81$24.915$25.13619.37K
Sep 4, 2026$25.37$25.69$25.18$25.57418.34K
Sep 3, 2026$26.50$26.90$25.45$25.62438.79K
Sep 2, 2026$26.93$27.92$26.29$26.34549.49K
Sep 1, 2026$27.05$27.95$26.915$27.09675.1K
Aug 31, 2026$26.46$27.10$25.86$26.99669.07K
Aug 28, 2026$26.71$27.11$26.685$26.77466.5K
Aug 27, 2026$26.92$27.34$26.58$26.67440.84K
Aug 26, 2026$26.18$27.42$26.02$27.20609.02K
Aug 25, 2026$26.89$27.145$26.19$26.38735.68K
Aug 24, 2026$28.01$28.165$26.77$26.891.04M
Aug 21, 2026$27.86$28.605$27.82$28.08485.22K
Aug 20, 2026$28.49$29.01$27.77$27.98819.36K
Aug 19, 2026$29.33$30.14$28.80$28.82679.12K
Aug 18, 2026$28.80$29.98$28.62$28.90846.92K
Aug 17, 2026$28.73$29.065$28.285$28.32496.15K

Latest AORT news

The latest Smart Investors Daily articles mentioning AORT.

Stock researchCompany · Overview

AORT research

Overview

Company profile and research snapshot.

Company profile

Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$47.50
Implied upside
—
Analysts
13
AORT recent ratings
DateFirmRatingTarget
Aug 18, 2026Canaccord GenuityBuy—
Jul 20, 2026NeedhamBuy—
Jun 16, 2026Canaccord GenuityBuy—
May 8, 2026CitizensMarket Outperform—
May 8, 2026NeedhamBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 27, 2026

Artivion (AORT) Stock Looks Cheap On Cash Flow But Pricey On Sales

Artivion stock has delivered a 57.6% gain over the past three years, yet current valuation checks suggest the shares now sit close to their estimated intrinsic value, rather than offering a clear discount. With the Discounted Cash Flow (DCF) estimate and market multiples both pointing to pricing that looks broadly in line with fundamentals, the stock no longer looks obviously cheap or obviously expensive. Artivion is up 57.6% over three years. This means anyone looking at the stock today is...

Yahoo · Aug 27, 2026

Artivion (AORT) Bounces As AMDS Launch Narrative Keeps Fair Value In Focus

Artivion (AORT) has drawn fresh attention after recent share price swings, with the stock up 3.1% in the latest session but still down 38.8% year to date as of 27 August 2026. Artivion’s recent 1 day share price return of 3.11% comes after a 7 day share price decline of 5.62%, with the stock still showing a year to date share price loss of 38.82%. The 3 year total shareholder return is 55.25%, suggesting longer term holders have seen a very different experience to recent buyers. Balance...

Yahoo · Aug 25, 2026

1 High-Flying Stock to Own for Decades and 2 Facing Challenges

Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lofty expectations make them particularly susceptible to drawdowns when market sentiment shifts.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By